1 | relapse | 8,245 |
2 | restenosis | 2,443 |
3 | attrition | 1,322 |
4 | rebleeding | 516 |
5 | reinfection | 439 |
6 | flatus | 290 |
7 | nonunion | 267 |
8 | overtreatment | 242 |
9 | lapse | 205 |
10 | recidivism | 170 |
11 | institutionalization | 156 |
12 | reocclusion | 129 |
13 | tachyphylaxis | 109 |
14 | non-union | 107 |
15 | malunion | 100 |
16 | re-infection | 96 |
17 | recrudescence | 78 |
18 | presyncope | 71 |
19 | relapse/recurrence | 71 |
20 | re-bleeding | 70 |
21 | culling | 66 |
22 | ineligibility | 58 |
23 | co-intervention | 53 |
24 | cross-contamination | 45 |
25 | intolerability | 43 |
26 | over-treatment | 42 |
27 | vgf | 37 |
28 | pseudarthrosis | 35 |
29 | non-persistence | 33 |
30 | re-stenosis | 32 |
31 | reinjury | 30 |
32 | restenoses | 24 |
33 | redislocation | 21 |
34 | cross-infection | 20 |
35 | reulceration | 18 |
36 | cross-transmission | 17 |
37 | re-testing | 17 |
38 | defection | 16 |
39 | evaluability | 16 |
40 | re-injury | 14 |
41 | noncompletion | 13 |
42 | rebleed | 13 |
43 | redisplacement | 13 |
44 | reocclusions | 13 |
45 | blastulation | 12 |
46 | hyperenzymemia | 12 |
47 | re-occlusion | 12 |
48 | urge-to-smoke | 12 |
49 | oesophagogastrostomy | 11 |
50 | resedation | 11 |
51 | rti/sti | 11 |
52 | re-offending | 10 |
53 | restenosis/occlusion | 10 |
54 | bronchoaspiration | 9 |
55 | non-improvement | 9 |
56 | stroke/se | 9 |
57 | hipoxemia | 8 |
58 | mesosalpinx | 8 |
59 | lsnced4 | 7 |
60 | re-hemorrhage | 7 |
61 | restenosis/reocclusion | 7 |
62 | confession | 6 |
63 | mother-to-child-transmission | 6 |
64 | tuberculosis-iris | 6 |
65 | argyria | 5 |
66 | late-loss | 5 |
67 | supernovae | 5 |
68 | 'smoke | 4 |
69 | hiv-seropositivity | 4 |
70 | non-coverage | 4 |
71 | reabuse | 4 |
72 | reobstruction | 4 |
73 | sero-protection | 4 |
74 | haemopericardium | 3 |
75 | perosis | 3 |
76 | re-infestation | 3 |
77 | reexacerbation | 3 |
78 | screen-viewing | 3 |
79 | 35days | 2 |
80 | 47d | 2 |
81 | cmv-disease | 2 |
82 | death/mi/tlr | 2 |
83 | erythrosedimentation | 2 |
84 | homoanatoxin-a | 2 |
85 | imtila | 2 |
86 | monitoring/relapse | 2 |
87 | no-reflow/slow-flow | 2 |
88 | paba-serum-concentration | 2 |
89 | re-dislocation | 2 |
90 | re-fixations | 2 |
91 | trinucleotides | 2 |
92 | wrist-dysfunction | 2 |
93 | 101d | 1 |
94 | 2.5s | 1 |
95 | 2000mg/kbw | 1 |
96 | 5.5-0.5 | 1 |
97 | 50,000-100,0000/microl | 1 |
98 | 95min | 1 |
99 | acrolein/kg | 1 |
100 | admino-salicylates | 1 |
101 | angialgia | 1 |
102 | at1r-gα | 1 |
103 | bone-destruction | 1 |
104 | centres.there | 1 |
105 | cg-animals | 1 |
106 | cleaved-gfp | 1 |
107 | contamination/infection | 1 |
108 | debilitations | 1 |
109 | deoxidation-reoxygenation | 1 |
110 | early-feeding | 1 |
111 | enticement | 1 |
112 | fractures/dislocations | 1 |
113 | hadrontherapy | 1 |
114 | hard-event | 1 |
115 | hematopiesis | 1 |
116 | intervention/secondary | 1 |
117 | km5ys | 1 |
118 | large-arteries | 1 |
119 | lv-atrophy | 1 |
120 | mchsp70 | 1 |
121 | memory-impairment | 1 |
122 | micro-leaks | 1 |
123 | mkk4/7 | 1 |
124 | mycophenolate-mophetil | 1 |
125 | outcomes.response | 1 |
126 | palinesthesia | 1 |
127 | predonisolone | 1 |
128 | pregnancy.discontinuation | 1 |
129 | procyclicality | 1 |
130 | reocurrence | 1 |
131 | restenois | 1 |
132 | rqlo | 1 |
133 | skin-cancer | 1 |
134 | squint/amblyopia | 1 |
135 | stroke/hemorrhage | 1 |
136 | under-staging | 1 |
137 | verapamil-sr. | 1 |
138 | “true | 1 |
1 | 'smoke | 4 |
2 | 101d | 1 |
3 | 2.5s | 1 |
4 | 2000mg/kbw | 1 |
5 | 35days | 2 |
6 | 47d | 2 |
7 | 5.5-0.5 | 1 |
8 | 50,000-100,0000/microl | 1 |
9 | 95min | 1 |
10 | acrolein/kg | 1 |
11 | admino-salicylates | 1 |
12 | angialgia | 1 |
13 | argyria | 5 |
14 | at1r-gα | 1 |
15 | attrition | 1,322 |
16 | blastulation | 12 |
17 | bone-destruction | 1 |
18 | bronchoaspiration | 9 |
19 | centres.there | 1 |
20 | cg-animals | 1 |
21 | cleaved-gfp | 1 |
22 | cmv-disease | 2 |
23 | co-intervention | 53 |
24 | confession | 6 |
25 | contamination/infection | 1 |
26 | cross-contamination | 45 |
27 | cross-infection | 20 |
28 | cross-transmission | 17 |
29 | culling | 66 |
30 | death/mi/tlr | 2 |
31 | debilitations | 1 |
32 | defection | 16 |
33 | deoxidation-reoxygenation | 1 |
34 | early-feeding | 1 |
35 | enticement | 1 |
36 | erythrosedimentation | 2 |
37 | evaluability | 16 |
38 | flatus | 290 |
39 | fractures/dislocations | 1 |
40 | hadrontherapy | 1 |
41 | haemopericardium | 3 |
42 | hard-event | 1 |
43 | hematopiesis | 1 |
44 | hipoxemia | 8 |
45 | hiv-seropositivity | 4 |
46 | homoanatoxin-a | 2 |
47 | hyperenzymemia | 12 |
48 | imtila | 2 |
49 | ineligibility | 58 |
50 | institutionalization | 156 |
51 | intervention/secondary | 1 |
52 | intolerability | 43 |
53 | km5ys | 1 |
54 | lapse | 205 |
55 | large-arteries | 1 |
56 | late-loss | 5 |
57 | lsnced4 | 7 |
58 | lv-atrophy | 1 |
59 | malunion | 100 |
60 | mchsp70 | 1 |
61 | memory-impairment | 1 |
62 | mesosalpinx | 8 |
63 | micro-leaks | 1 |
64 | mkk4/7 | 1 |
65 | monitoring/relapse | 2 |
66 | mother-to-child-transmission | 6 |
67 | mycophenolate-mophetil | 1 |
68 | no-reflow/slow-flow | 2 |
69 | non-coverage | 4 |
70 | non-improvement | 9 |
71 | non-persistence | 33 |
72 | non-union | 107 |
73 | noncompletion | 13 |
74 | nonunion | 267 |
75 | oesophagogastrostomy | 11 |
76 | outcomes.response | 1 |
77 | over-treatment | 42 |
78 | overtreatment | 242 |
79 | paba-serum-concentration | 2 |
80 | palinesthesia | 1 |
81 | perosis | 3 |
82 | predonisolone | 1 |
83 | pregnancy.discontinuation | 1 |
84 | presyncope | 71 |
85 | procyclicality | 1 |
86 | pseudarthrosis | 35 |
87 | re-bleeding | 70 |
88 | re-dislocation | 2 |
89 | re-fixations | 2 |
90 | re-hemorrhage | 7 |
91 | re-infection | 96 |
92 | re-infestation | 3 |
93 | re-injury | 14 |
94 | re-occlusion | 12 |
95 | re-offending | 10 |
96 | re-stenosis | 32 |
97 | re-testing | 17 |
98 | reabuse | 4 |
99 | rebleed | 13 |
100 | rebleeding | 516 |
101 | recidivism | 170 |
102 | recrudescence | 78 |
103 | redislocation | 21 |
104 | redisplacement | 13 |
105 | reexacerbation | 3 |
106 | reinfection | 439 |
107 | reinjury | 30 |
108 | relapse | 8,245 |
109 | relapse/recurrence | 71 |
110 | reobstruction | 4 |
111 | reocclusion | 129 |
112 | reocclusions | 13 |
113 | reocurrence | 1 |
114 | resedation | 11 |
115 | restenois | 1 |
116 | restenoses | 24 |
117 | restenosis | 2,443 |
118 | restenosis/occlusion | 10 |
119 | restenosis/reocclusion | 7 |
120 | reulceration | 18 |
121 | rqlo | 1 |
122 | rti/sti | 11 |
123 | screen-viewing | 3 |
124 | sero-protection | 4 |
125 | skin-cancer | 1 |
126 | squint/amblyopia | 1 |
127 | stroke/hemorrhage | 1 |
128 | stroke/se | 9 |
129 | supernovae | 5 |
130 | tachyphylaxis | 109 |
131 | trinucleotides | 2 |
132 | tuberculosis-iris | 6 |
133 | under-staging | 1 |
134 | urge-to-smoke | 12 |
135 | verapamil-sr. | 1 |
136 | vgf | 37 |
137 | wrist-dysfunction | 2 |
138 | “true | 1 |
1 | verapamil-sr. | 1 |
2 | mchsp70 | 1 |
3 | lsnced4 | 7 |
4 | 5.5-0.5 | 1 |
5 | mkk4/7 | 1 |
6 | homoanatoxin-a | 2 |
7 | angialgia | 1 |
8 | hyperenzymemia | 12 |
9 | hipoxemia | 8 |
10 | squint/amblyopia | 1 |
11 | argyria | 5 |
12 | palinesthesia | 1 |
13 | imtila | 2 |
14 | 101d | 1 |
15 | 47d | 2 |
16 | rebleed | 13 |
17 | supernovae | 5 |
18 | recrudescence | 78 |
19 | relapse/recurrence | 71 |
20 | reocurrence | 1 |
21 | non-persistence | 33 |
22 | re-hemorrhage | 7 |
23 | stroke/hemorrhage | 1 |
24 | non-coverage | 4 |
25 | 'smoke | 4 |
26 | urge-to-smoke | 12 |
27 | predonisolone | 1 |
28 | presyncope | 71 |
29 | centres.there | 1 |
30 | stroke/se | 9 |
31 | cmv-disease | 2 |
32 | outcomes.response | 1 |
33 | lapse | 205 |
34 | relapse | 8,245 |
35 | monitoring/relapse | 2 |
36 | reabuse | 4 |
37 | “true | 1 |
38 | vgf | 37 |
39 | acrolein/kg | 1 |
40 | early-feeding | 1 |
41 | re-bleeding | 70 |
42 | rebleeding | 516 |
43 | re-offending | 10 |
44 | under-staging | 1 |
45 | culling | 66 |
46 | re-testing | 17 |
47 | screen-viewing | 3 |
48 | rti/sti | 11 |
49 | mycophenolate-mophetil | 1 |
50 | 50,000-100,0000/microl | 1 |
51 | recidivism | 170 |
52 | haemopericardium | 3 |
53 | 95min | 1 |
54 | non-union | 107 |
55 | malunion | 100 |
56 | nonunion | 267 |
57 | confession | 6 |
58 | mother-to-child-transmission | 6 |
59 | cross-transmission | 17 |
60 | re-occlusion | 12 |
61 | restenosis/occlusion | 10 |
62 | reocclusion | 129 |
63 | restenosis/reocclusion | 7 |
64 | reexacerbation | 3 |
65 | re-dislocation | 2 |
66 | redislocation | 21 |
67 | resedation | 11 |
68 | blastulation | 12 |
69 | deoxidation-reoxygenation | 1 |
70 | cross-contamination | 45 |
71 | reulceration | 18 |
72 | bronchoaspiration | 9 |
73 | paba-serum-concentration | 2 |
74 | erythrosedimentation | 2 |
75 | re-infestation | 3 |
76 | pregnancy.discontinuation | 1 |
77 | institutionalization | 156 |
78 | defection | 16 |
79 | re-infection | 96 |
80 | cross-infection | 20 |
81 | contamination/infection | 1 |
82 | reinfection | 439 |
83 | sero-protection | 4 |
84 | wrist-dysfunction | 2 |
85 | reobstruction | 4 |
86 | bone-destruction | 1 |
87 | noncompletion | 13 |
88 | attrition | 1,322 |
89 | co-intervention | 53 |
90 | rqlo | 1 |
91 | cleaved-gfp | 1 |
92 | skin-cancer | 1 |
93 | death/mi/tlr | 2 |
94 | 2.5s | 1 |
95 | trinucleotides | 2 |
96 | large-arteries | 1 |
97 | restenoses | 24 |
98 | admino-salicylates | 1 |
99 | restenois | 1 |
100 | tuberculosis-iris | 6 |
101 | hematopiesis | 1 |
102 | re-stenosis | 32 |
103 | restenosis | 2,443 |
104 | perosis | 3 |
105 | pseudarthrosis | 35 |
106 | tachyphylaxis | 109 |
107 | micro-leaks | 1 |
108 | cg-animals | 1 |
109 | reocclusions | 13 |
110 | fractures/dislocations | 1 |
111 | debilitations | 1 |
112 | re-fixations | 2 |
113 | late-loss | 5 |
114 | flatus | 290 |
115 | km5ys | 1 |
116 | 35days | 2 |
117 | redisplacement | 13 |
118 | enticement | 1 |
119 | non-improvement | 9 |
120 | memory-impairment | 1 |
121 | over-treatment | 42 |
122 | overtreatment | 242 |
123 | hard-event | 1 |
124 | 2000mg/kbw | 1 |
125 | no-reflow/slow-flow | 2 |
126 | mesosalpinx | 8 |
127 | lv-atrophy | 1 |
128 | oesophagogastrostomy | 11 |
129 | hadrontherapy | 1 |
130 | intervention/secondary | 1 |
131 | re-injury | 14 |
132 | reinjury | 30 |
133 | procyclicality | 1 |
134 | intolerability | 43 |
135 | evaluability | 16 |
136 | ineligibility | 58 |
137 | hiv-seropositivity | 4 |
138 | at1r-gα | 1 |